Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

被引：3
|
作者：
Smedby, Karin Ekstrom Ekstroem [1 ,2 ]
Ekberg, Sara [2 ]
Eloranta, Sandra [2 ]
Enblad, Gunilla [3 ]
Jerkeman, Mats [4 ]
Andersson, Per-Ola
Harrysson, Sara [2 ,5 ]
机构：
[1] Karolinska Univ Hosp, Stockholm, Sweden
[2] Karolinska Inst, Div Clin Epidemiol, Dept Med Solna, Stockholm, Sweden
[3] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[4] Lund Univ, Inst Clin Sci, Dept Pathol & Oncol, Lund, Sweden
[5] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123785
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4111
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Outcome of salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), and diffuse large B-cell lymphoma (DLBCL).
    Wu, G.
    Kuruvilla, J.
    Nagy, T.
    Keating, A.
    Crump, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 348S - 348S
  • [22] Relapsed and refractory primary mediastinal diffuse large B-Cell lymphoma: Outcome with ICE-Based treatment.
    Hamlin, Paul A.
    Dickson, Mark
    Kewalramani, Tarun
    Horwitz, Steven M.
    Portlock, Carol S.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2006, 108 (11) : 870A - 870A
  • [23] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [24] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
  • [25] Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
    Garcia-Sancho, Alejandro Martin
    Cabero, Almudena
    Gutierrez, Norma C.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [26] Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma
    Bojanini, Leyla
    Gupta, Neel
    Khaki, Ali Raza
    ONCOLOGIST, 2023, 28 (09): : 750 - 751
  • [27] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [28] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands
    Pennings, Elise R. A.
    Durmaz, Mujde
    Visser, Otto
    Posthuma, Eduardus F. M.
    Issa, Djamila E.
    Chamuleau, Martine E. D.
    Lugtenburg, Pieternella
    Kersten, Marie Jose
    Dinmohamed, Avinash G.
    BLOOD, 2022, 140 : 9564 - 9565
  • [30] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
12345